STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.

The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.

Sutro Biopharma (NASDAQ: STRO) terrà un giorno di Ricerca e Sviluppo virtuale il mercoledì 12 novembre 2025 per presentare l'innovazione della piattaforma e il portafoglio ADC di prossima generazione.

La trasmissione web in diretta inizia alle 7:00 AM PT / 10:00 AM ET; gli investitori possono accedere alla trasmissione audio sulla pagina degli eventi delle relazioni con gli investitori della società e una replica archiviata sarà pubblicata dopo l'evento.

Sutro Biopharma (NASDAQ: STRO) organizará un Día de Investigación y Desarrollo virtual el miércoles 12 de noviembre de 2025 para presentar su innovación de plataforma y la cartera de ADC de nueva generación.

La transmisión en vivo comienza a las 7:00 AM PT / 10:00 AM ET; los inversores pueden acceder a la transmisión de audio en la página de eventos de relaciones con inversores de la empresa y se publicará una reproducción archivada después del evento.

Sutro Biopharma (NASDAQ: STRO)연구 개발의 날이라는 가상 행사를 2025년 11월 12일 수요일에 개최하여 플랫폼 혁신과 차세대 ADC 파이프라인을 발표합니다.

라이브 웨비스트는 오전 7:00 PT / 오후 10:00 ET에 시작되며, 투자자들은 회사의 투자자 관계 이벤트 페이지에서 오디오 웨비스트에 접속할 수 있고 이벤트 후에 보관 재생이 게시됩니다.

Sutro Biopharma (NASDAQ: STRO) organisera une Journée Recherche et Développement virtuelle le mercredi 12 novembre 2025 pour présenter son innovation de plateforme et son pipeline ADC de nouvelle génération.

La diffusion en direct commence à 7h00 PT / 10h00 ET ; les investisseurs peuvent accéder à la diffusion audio sur la page des événements des relations investisseurs de l'entreprise et une rediffusion archivée sera publiée après l'événement.

Sutro Biopharma (NASDAQ: STRO) wird einen virtuellen Forschungs- und Entwicklungstag am Mittwoch, dem 12. November 2025 veranstalten, um Innovationen der Plattform und die Next-Generation-ADC-Pipeline vorzustellen.

Die Live-Übertragung beginnt um 7:00 Uhr PT / 10:00 Uhr ET; Investoren können auf die Audio-Webcast-Seite der Investor Relations-Events des Unternehmens zugreifen, und eine archivierte Wiedergabe wird nach der Veranstaltung veröffentlicht.

Sutro Biopharma (NASDAQ: STRO) ستعقد يوم البحث والتطوير افتراضي في يوم الأربعاء 12 نوفمبر 2025 لعرض ابتكار منصتها وخطة ADC من الجيل التالي.

تبدأ البث المباشر في الساعة 7:00 صباحًا بتوقيت المحيط الهادئ / 10:00 صباحًا بتوقيت الشرقية؛ يمكن للمستثمرين الوصول إلى البث الصوتي على صفحة فعاليات العلاقات مع المستثمرين بالشركة وسيتم نشر إعادة تشغيل أرشيفية بعد الحدث.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.

The live webcast will be held on Wednesday, November 12, 2025, starting at 7:00AM PT / 10:00AM ET.

Webcast Information:
To access the live audio webcast, please go to https://ir.sutrobio.com/news-events/ir-calendar. An archived replay of the webcast will be available on the Company’s website following the event.

About Sutro Biopharma  
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com


FAQ

When is Sutro Biopharma's (STRO) virtual Research & Development Day?

The event is on Wednesday, November 12, 2025, starting at 7:00 AM PT / 10:00 AM ET.

How can investors access the Sutro (STRO) live webcast on November 12, 2025?

Access the live audio webcast via the company's investor relations events page at https://ir.sutrobio.com/news-events/ir-calendar.

Will Sutro (STRO) provide a replay of the November 12, 2025 R&D Day webcast?

Yes. An archived replay of the webcast will be available on the company's website following the event.

What topics will Sutro Biopharma (STRO) cover during the R&D Day on November 12, 2025?

The presentation will highlight platform innovation and the company's next‑generation ADC pipeline.

What time should East Coast investors tune in to Sutro (STRO) R&D Day on November 12, 2025?

The live webcast starts at 10:00 AM ET on November 12, 2025.
Sutro Biopharma

NASDAQ:STRO

STRO Rankings

STRO Latest News

STRO Latest SEC Filings

STRO Stock Data

86.47M
80.78M
4.6%
62.93%
3.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO